株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaLeaders:CROベンチマークレポート-主要CROの財務実績ベンチマーキング&競合情勢評価

PharmaLeaders: CRO Benchmark Report - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs

発行 GlobalData 商品コード 279163
出版日 ページ情報 英文 173 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaLeaders:CROベンチマークレポート-主要CROの財務実績ベンチマーキング&競合情勢評価 PharmaLeaders: CRO Benchmark Report - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs
出版日: 2013年08月19日 ページ情報: 英文 173 Pages
概要

当レポートでは、Global Dataの独自ランキング手法を用いて、17の財務メトリクスに関する主要CRO(医薬品開発業務受託機関)11社の競合ポジションを比較しており、財務実績、費用抑制、資本構造および企業活用に基づいた分析から、これらの企業がステークホルダーにとっての価値を高めるために利用するさまざまな戦略を明らかにしており、3つのサービスラインおよび4地域それぞれの分析、CRO市場および各企業の将来の競合ポジションの展望をまとめ、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 CRO(医薬品開発業務受託機関)市場の力学

  • アウトソーシングサービスデリバリーモデル
  • Quintilesが株式を公開
  • 弱い前臨床サービス需要がCRO節減の原因に
  • CROは生物製剤製造の専門企業へ移行
  • アジアの新興地域は最大の投資・成長を経験
  • e臨床技術は製品化までの時間を加速させる主要な促進因子

第4章 コラボレーション・買収戦略

  • 概要
  • M&A分析
  • 大手製薬企業クライアントとの戦略的提携

第5章 財務管理

  • CRO市場の競合情勢評価
  • 財務管理:ヒートマップ
  • 財務実績メトリクス

第6章 費用管理

  • CRO市場の競合情勢評価
  • 費用管理:ヒートマップ
  • 費用実績メトリクス

第7章 サービス分析

  • 概要
  • 臨床ラボサービス情勢評価
  • 収益・成長のリーダー企業
  • 製造サービス情勢評価
  • 収益・成長のリーダー企業
  • アドバイザリー・サポートサービス情勢評価
  • 収益・成長のリーダー企業

第8章 地域分析

  • 概要
  • 北米情勢の評価
  • 地域別の発展動向
  • 収益・成長のリーダー企業
  • 欧州情勢の評価
  • 地域別の発展動向
  • 収益・成長のリーダー企業
  • アジア太平洋地域情勢の評価
  • 地域別の発展動向
  • 収益・成長のリーダー企業
  • 新興市場情勢の評価
  • 地域別の発展動向
  • 収益・成長のリーダー企業

第9章 リソース管理戦略

  • 概要
  • オペレーション・世界的なサービスデリバリー
  • 企業活用:ヒートマップ
  • 企業活用メトリクス
  • 人的資本リーダーシップの変化
  • 資本管理:ヒートマップ
  • 資本構造メトリクス
  • 株式公開・債務再編

第10章 将来の展望

  • CRO市場
  • ベンダーのポジショニング

第11章 付録

図表リスト

目次
Product Code: GDHC002PLR

Summary

The CRO Benchmark Report applies GlobalData's proprietary ranking methodology to compare the competitive positions of 11 leading CRO companies on 17 financial metrics. These companies are analyzed based on financial performance, cost-containment, capital structure and firm utilization to illustrate the different strategies these companies are using to increase value for their shareholders. Throughout the report, GlobalData's Industry Dynamics Team provides you with expert insight, expanding on each of the metrics discussed. In addition to the financial metrics, this report discusses trends impacting the CRO marketplace, along with partnering and acquisition activity, and operations strategy. This report also provides drill-down analyses of three service lines and four geographies examining each of these segment's revenue and growth leaders, and business development strategies. Lastly, this report provides GlobalData's outlook on the CRO sector and each company's future competitive position.

Highlights

About the Report

The CRO market is highly fragmented comprised of some 1,000 individual companies, most of which are privately owned. These companies vary significantly in size and breadth of services - from a four person bioanalysis research lab in Thailand to companies like Quintiles and Covance which have tens of thousands of employees in over 100 countries across the globe. GlobalData identified 11 CROs to apply its benchmarking methodology providing a foundation for strategic discussion and analysis. GlobalData's coverage examines these CROs from a unique company-centric lens - combining financial performance and resources allocation with partnering activity and regional developments to assess a company's overall strategy. This type of coverage is unlike any other analysis available, and delivers a consistent view into the evolution of these companies corporate growth. We also covered some 30 other privately-held CROs to give our analysis more specificity and granularity.

Key Questions Answered

  • What specific strategies are these CROs employing to gain market share?
  • What drivers accounted for the revenue growth for the company over the past year?
  • Which trends will affect the CRO marketplace over the next few years?
  • What particular services or capabilities are my competitors developing?
  • Who are the revenue and growth leaders in each service line and geography?
  • What specific business development activities are taking place, in terms of partnerships or M&A?
  • How are CROs growing their physical infrastructures and human resources to better serve the needs of their customers?
  • What region-specific operations and capabilities are CROs adding to gain share in emerging markets?

Scope

  • Analysis of the key drivers and trends shaping the global CRO market; including biologics manufacturing, emerging markets, and eClinical technologies
  • A deep dive into the synergies behind partnering and acquisition activity
  • Discussion of business line and regional segment strategies
  • Assessments of company financials by revenue, margin, expense and capital structure
  • Firm utilization, resources management, and efficiency metrics
  • Leadership/management changes

Reasons to buy

  • Analyze and track the strategies that these CROs are using to gain share in the increasingly competitive market
  • Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending and asset structure
  • Organize your sales and marketing strategy to identify companies with proprietary technologies to maximize opportunities for strategic investment or partnerships
  • Use this information as an independent source for your due diligence and transaction strategy

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
    • 2.1.1. GlobalData Selection Criteria
    • 2.1.2. Companies Financially Benchmarked
    • 2.1.3. Other Companies Covered
  • 2.2. Upcoming Reports
  • 2.3. Recently Published Reports
  • 2.4. GlobalData's Benchmarking Methodology
  • 2.5. GlobalData CRO Benchmark Leader: EPS Corporation

3. CRO Market Dynamics

  • 3.1. Outsourcing Service Delivery Models
    • 3.1.1. Fully Integrated Service Model
    • 3.1.2. Functional Service Model
    • 3.1.3. The Bottom Line: Use a Hybrid Approach
  • 3.2. Quintiles Goes Public
    • 3.2.1. Quintiles IPO Raises $947M, Pricing an Increased Number of Shares at Top Range
  • 3.3. Weak Demand for Preclinical Services Causes CROs to Economize
  • 3.4. CROs Are Transitioning into Becoming Experts in Biologics Manufacturing
    • 3.4.1. WuXi Will Become a Leader in Biologics Manufacturing through its Multi-pronged Strategy
    • 3.4.2. Catalent Opens New Manufacturing Center for Biologic Drug Development
    • 3.4.3. ShangPharma Inks Two mAb Partnerships
  • 3.5. Emerging Locations in Asia Will See the Greatest Investment and Growth
    • 3.5.1. Location, Location - Footprint Growth Has Become More Important than Cost Reduction
    • 3.5.2. Will Concerns about Patient Safety Bring Down the Indian Clinical Trial Market?
  • 3.6. eClinical Technologies Will be Key Drivers to Accelerating Time-to-Market
    • 3.6.1. Icon and Cerner Team Up to Streamline Late-Phase Studies
    • 3.6.2. Parexel Introduces MyTrials Platform
    • 3.6.3. INC Research Expands Partnership with Medidata Solutions
    • 3.6.4. Quintiles Unveils its Next-Generation Infosario Analytics Platform
    • 3.6.5. Covance Launches Xcellerate to Increase Clinical Trial Optimization

4. Collaboration and Acquisition Strategies

  • 4.1. Overview
  • 4.2. M&A Analysis
    • 4.2.1. KKR Makes a Splash into CRO Biz with PRA Buy
    • 4.2.2. Quintiles Invests in Personalized Medicine
    • 4.2.3. Patheon Completes Purchase of Banner Pharmacaps
    • 4.2.4. Clinipace Doubles in Size with Paragon Buyout
    • 4.2.5. Accenture Complements its R&D Service Offerings with Acquisition of Octagon
    • 4.2.6. Catalent Pharma Buys Aptuit's CTS Business
    • 4.2.7. Charles River and Covance Expand Microbial Identification Capabilities
  • 4.3. Strategic Partnerships with Large Pharmaceutical Clients
    • 4.3.1. Quintiles and Merck Serono Announce Innovative Clinical Development Partnership
    • 4.3.2. Charles River and AstraZeneca Align to Accelerate Drug Development
    • 4.3.3. Covance Deals
    • 4.3.4. Pfizer Improves Clinical Trial Flexibility with Icon and Parexel Partnership
    • 4.3.5. Aptuit and GSK Extend Strategic Alliance
    • 4.3.6. INC Research Enters into FSP Collaboration with Astellas
    • 4.3.7. PRA Announces Strategic Biosimilar Development Agreement with Amgen
    • 4.3.8. Parexel and Catalent Combine Core Competencies to Streamline Supply Chain

5. Financial Management

  • 5.1. CRO Market Competitive Landscape Assessment
    • 5.1.1. As Quintiles Goes, So Goes the CRO Market
  • 5.2. Financial Management: Heat Map
    • 5.2.1. Quintiles Was the Financial Management Leader in 2012
  • 5.3. Financial Performance Metrics
    • 5.3.1. Revenue
    • 5.3.2. Revenue Growth YtY
    • 5.3.3. Operating Income
    • 5.3.4. Operating Income Growth YtY
    • 5.3.5. Operating Margin

6. Expense Management

  • 6.1. CRO Market Competitive Landscape Assessment
    • 6.1.1. Cost Containment Remains a Strategic Driver for CROs
  • 6.2. Expense Management: Heat Map
    • 6.2.1. CMIC Was the Expense Management Leader in 2012
  • 6.3. Expense Performance Metrics
    • 6.3.1. S,G&A Expense
    • 6.3.2. G&A Expense as a Percentage of Revenue
    • 6.3.3. S&M Expense as a Percentage of Revenue
    • 6.3.4. Total OpEx as a Percentage of Revenue

7. Services Analysis

  • 7.1. Overview
  • 7.2. Clinical Laboratory Services Landscape Assessment
    • 7.2.1. Demand for Clinical Lab Services is Fueling Overall Market Growth
    • 7.2.2. Expand Delivery of Clinical Laboratory Services
    • 7.2.3. Quintiles Forms New Biomarker Research and Development Company
  • 7.3. Revenue and Growth Leaders
    • 7.3.1. Revenue
    • 7.3.2. Revenue Growth YtY
  • 7.4. Manufacturing Services Landscape Assessment
    • 7.4.1. Catalent Solidifies its Position as a Leading Provider of CMO Services
    • 7.4.2. Aptuit Launches New Approach to CMC
    • 7.4.3. API Supply Agreements
  • 7.5. Revenue and Growth Leaders
    • 7.5.1. Revenue
    • 7.5.2. Revenue Growth YtY
  • 7.6. Advisory and Support Services Landscape Assessment
    • 7.6.1. Catalent's Acquisition of Aptuit's CTS Business Drove Advisory Revenues in 2012
    • 7.6.2. Strategic Advisory Services
    • 7.6.3. Staffing and Customer Support Services
  • 7.7. Revenue and Growth Leaders
    • 7.7.1. Revenue
    • 7.7.2. Revenue Growth YtY

8. Regional Analysis

  • 8.1. Overview
  • 8.2. North America Landscape Assessment
    • 8.2.1. Pharma's Large Revenue Base in North America Continues to Drive CRO Sector Growth
  • 8.3. Regional Developments
    • 8.3.1. Covance Collaborates with M2Gen and BioPontis Alliance
    • 8.3.2. AMRI Signs Agreement to License its Novel Tubulin Inhibitor Program to Chai Therapeutics
    • 8.3.3. Ockham Completes Acquisition of Nexus Oncology
    • 8.3.4. Synteract and HCR Combine to Form Multinational CRO
    • 8.3.5. Accelovance Buys Radiant's CRO Division
    • 8.3.6. Frontage Inks Deal with AtheroNova
    • 8.3.7. Pharm-Olam Completes Phase III Ophthalmology Study for InSite Vision
  • 8.4. Revenue and Growth Leaders
    • 8.4.1. Revenue
    • 8.4.2. Revenue Growth YtY
  • 8.5. Europe Landscape Assessment
    • 8.5.1. European CRO Market Witnessed a Significant Pullback in Growth
  • 8.6. Regional Developments
    • 8.6.1. TFS International Acquires Italian CRO Dimensione Ricerca
    • 8.6.2. Quintiles Signs Deal to Bring Almirall's LAMA Therapy to the UK
    • 8.6.3. Icon Selected by European Pharma Companies as a Global Strategic Partner
    • 8.6.4. CromSource Adds Early-Phase Research Unit in Partnership with CRC
    • 8.6.5. Covance Inks Tech Transfer Deal with France's Inserm Transfert SA
  • 8.7. Revenue and Growth Leaders
    • 8.7.1. Revenue
    • 8.7.2. Revenue Growth YtY
  • 8.8. Asia-Pacific Landscape Assessment
    • 8.8.1. APAC Market Remains Hot for Clinical Outsourcing
  • 8.9. Regional Developments
    • 8.9.1. Japanese CROs Grow their Domestic Footprints
    • 8.9.2. AMRI Drives SmartSourcing Strategy in Japan
    • 8.9.3. Covance-BML Boost Clinical Trial Lab in Japan
    • 8.9.4. Frontage Hired by Local Chinese Clients to Develop Drugs Overseas
  • 8.10. Revenue and Growth Leaders
    • 8.10.1. Revenue
    • 8.10.2. Revenue Growth YtY
  • 8.11. Emerging Markets Landscape Assessment
    • 8.11.1. BRICs and Other Emerging Regions Still Represent Huge Untapped Markets for R&D
  • 8.12. Regional Developments
    • 8.12.1. Central and Latin America
    • 8.12.2. Emerging EMEA
    • 8.12.3. China
    • 8.12.4. India
    • 8.12.5. Rest of Asia
  • 8.13. Revenue and Growth Leaders
    • 8.13.1. Revenue
    • 8.13.2. Revenue Growth YtY

9. Resource Management Strategies

  • 9.1. Overview
  • 9.2. Operations and Global Service Delivery
    • 9.2.1. Expand Strategic Investment in Emerging Markets to Support Business Growth
    • 9.2.2. PPD and Icon Grow Bioassay Capabilities in the US and Europe
    • 9.2.3. EPS Corporation Separates Business Units to Streamline Efficiency
    • 9.2.4. AMRI Realigns its Drug Discovery Services
    • 9.2.5. Laboratory Accreditations and Certifications
  • 9.3. Firm Utilization: Heat Map
    • 9.3.1. Covance Was the Firm Utilization Leader in 2012
  • 9.4. Firm Utilization Metrics
    • 9.4.1. Headcount Growth YtY
    • 9.4.2. Revenue per Employee
    • 9.4.3. Clinical Services Revenue per Clinical Services Employee
    • 9.4.4. G&A Expense per G&A Employee
    • 9.4.5. S&M Expense per S&M Employee
  • 9.5. Human Capital Leadership Changes
    • 9.5.1. Source Therapeutic and Regional Expertise to Boost Clinical Operations
  • 9.6. Capital Management: Heat Map
    • 9.6.1. EPS Was the Capital Management Leader in 2012 due to its Higher Liquidity
  • 9.7. Capital Structure Metrics
    • 9.7.1. Debt/Equity Ratio
    • 9.7.2. Current Ratio
    • 9.7.3. Cash Ratio
  • 9.8. Share Offerings and Debt Restructurings
    • 9.8.1. Proceeds from Share Repurchases Used to Pay-down Debt and Finance Acquisitions

10. Future Outlook

  • 10.1. CRO Market
  • 10.2. Vendor Positioning

11. Appendix

  • 11.1. Research Methodology
    • 11.1.1. Coverage
    • 11.1.2. Secondary Research
  • 11.2. About the Author
    • 11.2.1. Adam Dion, Industry Analyst
  • 11.3. Director, Healthcare Industry Dynamics
  • 11.4. Global Head of Healthcare
  • 11.5. About the Industry Dynamics Team
  • 11.6. About GlobalData
  • 11.7. Disclosure Information
  • 11.8. Disclaimer

List of Tables

  • Table 1: GlobalData Benchmark Rankings, Contract Research Organizations, 2012
  • Table 2: Financial Management Composite Scores, 2012
  • Table 3: Expense Management Composite Scores, 2012
  • Table 4: Infrastructure Investments, Emerging Markets, 2012-2013
  • Table 5: Infrastructure Investments, US and Europe, 2012-2013
  • Table 6: Recent Laboratory Accreditations and Certifications, Worldwide, 2012-2013
  • Table 7: Firm Utilization Composite Scores, 2012
  • Table 8: Key Leadership Changes, 2012-2013
  • Table 9: Capital Management Composite Scores, 2012
  • Table 10: Share Offerings and Debt Restructurings, 2012-2013

List of Figures

  • Figure 1: Contract Research Organization Deals and Deal Values ($m), 2008-2012
  • Figure 2: Number of M&A Deals and Deal Values ($m), 2008-2012
  • Figure 3: Number of Licensing Deals and Deal Values ($m), 2008-2012
  • Figure 4: Leading CRO Landscape Assessment - FY2012 Revenue Growth vs. Operating Margin
  • Figure 5: Revenue ($m) by Company, 2012
  • Figure 6: Revenue Growth by Company, 2012
  • Figure 7: Operating Income ($m) by Company, 2012
  • Figure 8: Operating Income Growth by Company, 2012
  • Figure 9: Operating Margin by Company, 2012
  • Figure 10: Leading CRO Landscape Assessment - FY2012 S,G&A Expense vs. Total OpEx
  • Figure 11: S,G&A Expense ($m) by Company, 2012
  • Figure 12: G&A Expense as a Percentage of Revenue by Company, 2012
  • Figure 13: S&M Expense as a Percentage of Revenue by Company, 2012
  • Figure 14: Total OpEx Spending as a Percentage of Revenue by Company, 2012
  • Figure 15: Combined Peer Group Revenue ($m) by Service Line, 2010-2012
  • Figure 16: Clinical Lab Services Landscape, 2012
  • Figure 17: Clinical Laboratory Services Revenue ($m) by Company, 2012
  • Figure 18: Clinical Laboratory Services Revenue Growth by Company, 2012
  • Figure 19: Manufacturing Services Landscape, 2012
  • Figure 20: Manufacturing Services Revenue ($m) by Company, 2012
  • Figure 21: Manufacturing Services Revenue Growth by Company, 2012
  • Figure 22: Advisory and Support Services Landscape, 2012
  • Figure 23: Advisory and Support Services Revenue ($m) by Company, 2012
  • Figure 24: Advisory and Support Services Revenue Growth by Company, 2012
  • Figure 25: Combined Peer Group Revenue ($m) by Region, 2010-2012
  • Figure 26: North America Landscape Assessment, 2012
  • Figure 27: North America Revenue ($m) by Company, 2012
  • Figure 28: North America Revenue Growth by Company, 2012
  • Figure 29: Europe Landscape Assessment, 2012
  • Figure 30: Europe Revenue ($m) by Company, 2012
  • Figure 31: Europe Revenue Growth by Company, 2012
  • Figure 32: APAC Landscape Assessment, 2012
  • Figure 33: APAC Revenue ($m) by Company, 2012
  • Figure 34: APAC Revenue Growth by Company, 2012
  • Figure 35: Emerging Markets Landscape Assessment, 2012
  • Figure 36: Emerging Markets Revenue ($m) by Company, 2012
  • Figure 37: Emerging Markets Revenue Growth by Company, 2012
  • Figure 38: Headcount Growth by Company, 2012
  • Figure 39: Revenue per Employee (In $ Thousands) by Company, 2012
  • Figure 40: Clinical Srvcs Revenue per Clinical Srvcs Employee (In $ Thousands) by Company, 2012
  • Figure 41: G&A Expense per G&A Employee (In $ Thousands) by Company, 2012
  • Figure 42: S&M Expense per S&M Employee (In $ Thousands) by Company, 2012
  • Figure 43: Debt-to-Equity Ratio by Company, 4Q12
  • Figure 44: Current Ratio by Company, 4Q12
  • Figure 45: Cash Ratio by Company, 4Q12
  • Figure 46: CRO Benchmark Peer Group, Global Market Forecast, ($bn), 2012-2017
  • Figure 47: CRO Benchmark Vendor Position and 2013 Growth Projections
Back to Top